Proceedings of the Texas A&M Medical Student Grand Rounds

The Therapeutic Use of HIF Pathway Inhibitors to Reduce Castrate Resistant Prostate Cancer

July 7, 2020 Gabrielle Young

Gabrielle Young

INTRODUCTION: Prostate cancer (PC) is the leading cause of cancer related death of men in American, and castration resistant prostate cancer (CRPC) is the major mortality determinant; therefore, it has a lot of importance.1,2 Previous studies conducted have verified the importance of the hypoxia inducible factor (HIF) pathway in the progression of PC to CRPC by providing convincing evidences of strong correlation between elevated levels of HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy.3,5,6  These studies have also shown the effect androgen deprivation therapy (ADT) induced hypoxia has on the transcriptional activity of HIF as an adaptive response.1,6  Resveratrol, a polyphenol found on the outside of red fruits, can stifle numerous sorts of malignancies including PC.3 By and by, its mechanism of action isn’t yet clear.3 Subsequently, this study meant to clarify its impact on PC cells.3 MATERIAL AND METHODS: The multiplication of prostate cancer cells was dictated by CCK-8 assay. Cell apoptosis was controlled by Hoechst staining folin-coicalteu assay. Cell migration was recognized by scratch test. The degrees of apoptosis-related protein were recognized by Western blot analysis. RESULTS: It was found that resveratrol suppresses cellular proliferation and migration and enhances cell death.3 What’s more, it was uncovered that resveratrol raised ROS concentration and the articulation of biomarker of cell death Bax, while repressing Bcl2, an anti-apoptotic protein, and strengthening expression of p53.3 Besides, resveratrol surprisingly increase the secretion of HIF-1α and p53 in PC cells.3 Resveratrol stifled cell proliferation and enhanced cell death, yet its effects were turned around after HIF-1α knockdown, suggesting that the impacts of resveratrol in PC are intervened by means of HIF-1α.3 CONCLUSION: The findings indicate that resveratrol induces apoptosis via HIF-1α/p53 signaling in prostate cancer cells and may be a useful therapeutic agent against prostate cancer. This therapeutic use is important given that a physician could prescribe a diet high in resveratrol in conjunction with other forms of therapy.

  1. O’Reilly D, D. (2020). Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer. – PubMed – NCBI. [online] Ncbi.nlm.nih.gov. Available at: https://www.ncbi.nlm.nih.gov/pubmed/31521707
  2. Reddy KR, Guan Y, Qin G, Zhou Z, Jing N. Combined treatment targeting HIF‐1α and Stat3 is a potent strategy for prostate cancer therapy. Wiley Online Library. https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.21397. Published April 7, 2011. Accessed April 6, 2020
  3. Wang, D., Gao, Z., & Zhang, X. (2018). Resveratrol Induces Apoptosis in Murine Prostate Cancer Cells via Hypoxia-Inducible Factor 1-alpha (HIF-1α)/Reactive Oxygen Species (ROS)/P53 Signaling. Medical science monitor : international medical journal of experimental and clinical research, 24, 8970–8976. https://doi-org.srv-proxy2.library.tamu.edu/10.12659/MSM.913290
  4. Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. Annu Rev Med. 2019;70:479–499. doi:10.1146/annurev-med-051517-011947
  5. Bae KM, Dai Y, Vieweg J, Siemann DW. Hypoxia regulates SOX2 expression to promote prostate cancer cell invasion  and  sphere  Am  J  Cancer  Res. 2016;6(5):1078–1088. Published 2016 May 1.
  6. Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378–389. doi:10.1016/j.apsb.2015.05.007
Cancer
Previous Post

Human Induced Pluripotent Stem Cells as a Treatment for Parkinson’s Disease

Next Post

Efficacy of Calreticulin of the Unfolded Protein Response as a Drug Target in HNSCC

Scientific Editors

Steve A. Maxwell

Executive Editor
Tel: 979-436-0804
smaxwell@medicine.tamhsc.edu

Robin Fuchs-Young

Deputy Editor
Tel: 979-845-5109
fuchs-young@medicine.tamhsc.edu
Administrative Editor

Janis Chmiel

Tel: 979-436-0856
chmiel@medicine.tamhsc.edu
Editorial Office
Tel.: 979-845-2726
Fax: 979-847-9481
chmiel@medicine.tamhsc.edu
Archives
  • July 2026
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • May 2025
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • November 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • August 2022
  • June 2022
  • May 2022
  • August 2021
  • July 2021
  • April 2021
  • October 2020
  • August 2020
  • July 2020
  • August 2019
  • July 2019
  • February 2019
  • July 2018
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • January 2017
Proudly powered by WordPress | Theme: Fmi by Forrss.